COMBINATION THERAPY WITH TARGETED 4-1BB (CD137) AGONISTS

The present application relates to combination therapies employing tumor targeted anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules, the use of these combination therapies for the treatment of cancer and methods of using the c...

Full description

Saved in:
Bibliographic Details
Main Authors BACAC MARINA, FERRARA KOLLER CLAUDIA, LANG SABINE, LEVITSKI VIKTOR, KLEIN CHRISTIAN, UMANA PABLO, CLAUS CHRISTINA
Format Patent
LanguageChinese
English
Published 02.08.2019
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The present application relates to combination therapies employing tumor targeted anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies. The trimer CEA-4-1BBL (Figure IB) provides the highest tumor regression when combined with CEA CD3 TCB (See table 18). 本申请涉及采用肿瘤靶向性抗CD3双特异性抗体和4-1BB(CD137)激动剂,特别是含有4-1BBL三聚体的抗原结合分子的组合疗法,这些组合疗法用于治疗癌症的用途和使用该组合疗法的方法。三聚体CEA-4-1BBL(图1B)在与CEA CD3 TCB组合时提供最高肿瘤消退(见表18)。
Bibliography:Application Number: CN201780078076